NSE: APOLLOHOSP | BSE: 508869

Mid-range Performer

Download real time

7441.00 32.00 (0.43%)

236.0K NSE+BSE Volume

NSE 01 Oct, 2025 3:31 PM (IST)

106,990.2

Market Cap

Market Runner Up

0.8

Beta 1Year

Very Low volatility

Apollo Hospitals Enterprise Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APOLLOHOSP, BSE:508869 Apollo Hospitals Enterprise Ltd.

Search Inside the pdf :

Apollo Hospitals Enterprise Ltd.

14 Aug 2025

7441.00

0.43%

Apollo Hospitals Enterprise (APHS IN) Q1FY26 Result Update ...

Buy: Apollo Hospitals Enterpris...

Target

Prabhudas Lilladhar

Apollo Hospitals Enterprise (APHS) reported consolidated EBITDA of Rs8.5bn (up 26% YoY), was 6% above our estimates. Adjusted for 24x7 losses and ESOPs cost (~Rs1.2bn), EBITDA was Rs9.7bn, up 18% YoY. The recent stake sale in HealthCo to Advent and merger with Keimed are a positive step and will lead to an integrated pharmacy distribution business complemented by the fastgrowing omni-channel digital health business. Scale-up in Apollo HealthCo has been on track with likely breakeven in EBITDA of digital business over the next 3-4 quarters. The management guidance of Rs20bn EBITDA of the merged entity by FY28 provides comfort. Further, mgmt. has also announced the...

Apollo Hospitals Enterprise Ltd. is trading below its 30 day SMA of 7750.4

Apollo Hospitals Enterprise Ltd.

02 Jul 2025, 12:00AM

7441.00

0.43%

Apollo Hospitals Enterprise (APHS IN) Event Update Demerger...

Buy: Apollo Hospitals Enterpris...

Target

Prabhudas Lilladhar

to ensure non-compete and synergy alignment between AHEL and NewCo, with clear role demarcation - AHEL to focus on core healthcare and NewCo on pharmacy & digital. The demerger was on expected lines and is aimed to unlock value by creating a focused, high-growth platform in the pharmacy and digital healthcare space, which is more consumer centric in nature. The stake sale in HealthCo to Advent and merger with Keimed are a positive step and will lead to an integrated pharmacy distribution business. Scale-up in...

Apollo Hospitals Enterprise Ltd. is trading below its 30 day SMA of 7750.4

Apollo Hospitals Enterprise Ltd.

01 Jul 2025, 12:00AM

7441.00

0.43%

Strategic demerger sets stage for long-term value creation

Buy: Apollo Hospitals Enterpris...

Target

Motilal Oswal

The proposal to demerge the pharmacy business—including offline pharmacy, online and telehealth operations, and Kiemed—into NewCo bodes well for longterm value creation across both the healthcare services (hospital/clinics business) and pharmacy businesses.

Apollo Hospitals Enterprise Ltd. is trading above its 200 day SMA of 7069.1

Apollo Hospitals Enterprise Ltd.

16 Jun 2025

7441.00

0.43%

APOLLO HOSPITAL

Accumulate: Apollo Hospitals Enterpris...

Recommendation Target

Geojit BNP Paribas

Under HealthCo, offline pharmacy revenue grew 16.6% YoY to Rs. 2,084cr as store count rose to 6,626 (vs 6,360 in Q3FY25) and strong private-label sales. Online pharmacy sales grew 22.3% YoY to Rs. 292cr. Apollo got a boost as daily active...

Apollo Hospitals Ent.. has an average target of 8259.25 from 4 brokers.

Apollo Hospitals Enterprise Ltd.

01 Jun 2025, 12:00AM

7441.00

0.43%

Apollo Hospitals Enterprise (APHS IN) Q4FY25 Result Update ...

Buy: Apollo Hospitals Enterpris...

Prabhudas Lilladhar

Apollo Hospitals Enterprise (APHS) reported consolidated EBITDA of Rs7.7bn (up 20% YoY), was in line with our estimates. Adjusted for 24x7 losses and ESOPs cost (~Rs1.6bn), EBITDA was Rs9.3bn, up 18% YoY. The recent stake sale in HealthCo to Advent and merger with Keimed are a positive step and will lead to an integrated pharmacy distribution business complemented by the fastgrowing omni-channel digital health business. Scale-up in Apollo HealthCo has been on track with likely breakeven in EBITDA of digital business over the next...

Number of FII/FPI investors increased from 1548 to 1626 in Jun 2025 qtr.

Apollo Hospitals Enterprise Ltd.

31 May 2025

7441.00

0.43%

Operationally in-line 4Q; ends FY25 on a strong note

Buy: Apollo Hospitals Enterpris...

Target

Motilal Oswal

Apollo Hospitals Enterprises (APHS) posted marginally better-than-expected revenue (4% beat), while EBITDA was in line for the quarter. The lower tax rate led to better-than-expected earnings for the quarter.

Promoters unpledged 0.36% of shares in last quarter. Total pledge stands at 13.11% of promoter holdings

Apollo Hospitals Enterprise Ltd.

12 Feb 2025

7441.00

0.43%